Clinical trial results:
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)

Summary

EudraCT number	2016-001835-11
Trial protocol	ES AT FR IT
Global end of trial date	29 January 2020

Results information

Result version number	v1 (current)
This version publication date	12 February 2021
First version publication date	12 February 2021

Trial information

Trial identification

Sponsor protocol code	CA018-001

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Bristol-Myers Squibb
Sponsor organisation address	Chaussée de la Hulpe 185, Brussels, Belgium, 1170
Public contact	EU Study Start-Up Unit, Bristol-Myers Squibb International Corporation, Clinical.Trials@bms.com
Scientific contact	Bristol-Myers Squibb Study Director, Bristol-Myers Squibb, Clinical.Trials@bms.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	17 March 2020
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	29 January 2020
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the preliminary efficacy, safety, and tolerability of novel FRACTION-Lung treatment combinations in subjects with advanced non-small cell lung cancer (NSCLC).

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization Good Clinical Practice Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	06 May 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Austria: 2
Country: Number of subjects enrolled	Australia: 6
Country: Number of subjects enrolled	Canada: 23
Country: Number of subjects enrolled	France: 4
Country: Number of subjects enrolled	Italy: 25
Country: Number of subjects enrolled	Spain: 28
Country: Number of subjects enrolled	Switzerland: 1
Country: Number of subjects enrolled	United States: 206
Worldwide total number of subjects	295
EEA total number of subjects	59

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	149
From 65 to 84 years	146
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Each of the 295 subjects was assigned to 1 of 5 non-consecutive Tracks (based on previous therapy exposure and/or PD-1/PD-L1 expression). 14 of the 295 subjects, after receiving initial treatment, were re-randomized to a second, different treatment (either under a different Track or within the same Track).

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	No
Arm title	Nivolumab

Arm description:

Nivolumab monotherapy 240 mg Q2W administered until completion of 6 cycles (1 cycle=4 weeks)

Arm type	Experimental
Investigational medicinal product name	Nivolumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Flat dose 240 mg Q2W given as an IV over approximately 30 minutes

Arm title	Nivolumab + Dasatinib

Arm description:

Nivolumab 240 mg Q2W + Dasatinib 100 mg QD, administered until completion of 6 cycles (1 cycle=4 weeks)

Arm type	Experimental
Investigational medicinal product name	Nivolumab + Dasatinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection, Tablet
Routes of administration	Intravenous use, Oral use

Dosage and administration details:

Nivolumab: flat dose 240 mg Q2W Dasatinib: 100 mg QD

Arm title	Nivolumab + BMS986016

Arm description:

Nivolumab 240 mg Q2W + BMS986016 20 mg Q2W, administered until completion of 6 cycles (1 cycle=4 weeks)

Arm type	Experimental

Investigational medicinal product name	Nivolumab + BMS986016
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Nivolumab: flat dose 240 mg Q2W BMS986016: 20 mg Q2W

Arm title	Nivolumab + Ipilimumab

Arm description:

Nivolumab 240 mg Q2W for 12 doses + Ipilimumab 1 mg/kg Q6W for 4 doses, administered until completion of 24 weeks of study

Arm type	Experimental
Investigational medicinal product name	Nivolumab + Ipilimumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Nivolumab: flat dose 240 mg Q2W Ipilimumab: 1 mg/Kg Q6W

Arm title	Nivolumab + BMS986205

Arm description:

Nivolumab 480 mg Q4W + BMS986205 100 mg QD, administered until completion of 6 cycles (1 cycle=4 weeks

Arm type	Experimental
Investigational medicinal product name	Nivolumab + BMS986205
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection, Tablet
Routes of administration	Intravenous use, Oral use

Dosage and administration details:

Nivolumab: flat dose 240 mg Q2W BMS986205: 100 mg QD

Number of subjects in period 1	Nivolumab	Nivolumab + Dasatinib	Nivolumab + BMS986016
Started	49	104	17
Completed	16	9	1
Not completed	33	97	17
Subject withdrew consent	-	5	1
Disease progression	24	63	15
Subject request to discontinue	1	3	-
Study drug toxicity	5	12	-
Death	-	-	-
AE unrelated to study drug	2	6	1
Other reasons	1	8	-
Joined	0	2	1

Re-randomized to a second treatment	-	2	1

Number of subjects in period 1	Nivolumab + Ipilimumab	Nivolumab + BMS986205
Started	88	37
Completed	26	0
Not completed	67	43
Subject withdrew consent	-	-
Disease progression	52	34
Subject request to discontinue	1	3
Study drug toxicity	9	2
Death	1	-
AE unrelated to study drug	1	2
Other reasons	3	2
Joined	5	6
Re-randomized to a second treatment	5	6

Baseline characteristics

Reporting groups[1]	
Reporting group title	Nivolumab
Reporting group description:	
Nivolumab monotherapy 240 mg Q2W administered until completion of 6 cycles (1 cycle=4 weeks)	
Reporting group title	Nivolumab + Dasatinib
Reporting group description:	
Nivolumab 240 mg Q2W + Dasatinib 100 mg QD, administered until completion of 6 cycles (1 cycle=4 weeks)	
Reporting group title	Nivolumab + BMS986016
Reporting group description:	
Nivolumab 240 mg Q2W + BMS986016 20 mg Q2W, administered until completion of 6 cycles (1 cycle=4 weeks)	
Reporting group title	Nivolumab + Ipilimumab
Reporting group description:	
Nivolumab 240 mg Q2W for 12 doses + Ipilimumab 1 mg/kg Q6W for 4 doses, administered until completion of 24 weeks of study	
Reporting group title	Nivolumab + BMS986205
Reporting group description:	
Nivolumab 480 mg Q4W + BMS986205 100 mg QD, administered until completion of 6 cycles (1 cycle=4 weeks	

Notes:

[1] - The number of subjects reported to be in the baseline period is not equal to the worldwide number of subjects enrolled in the trial. It is expected that these numbers will be the same.
Justification: 14 subjects, after receiving a first treatment, were re-randomized to a second different treatment group

Reporting group values	Nivolumab	Nivolumab + Dasatinib	Nivolumab + BMS986016
Number of subjects	49	106	18
Age categorical Units: Subjects			
Adults (18-64 years)	24	49	8
From 65-84 years	25	57	10
Age Continuous Units: Years			
arithmetic mean	64.5	63.8	66.3
standard deviation	± 10.27	± 9.26	± 8.99
Sex: Female, Male Units: Participants			
Female	21	35	8
Male	28	71	10
Race (NIH/OMB) Units: Subjects			
Asian	2	7	2
Black or African American	0	6	1
White	42	87	15
Unknown or Not Reported	5	6	0
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	1	2	0
Not Hispanic or Latino	25	66	18

Unknown or Not Reported	23	38	0

Reporting group values	Nivolumab + Ipilimumab	Nivolumab + BMS986205	Total
Number of subjects	93	43	309
Age categorical Units: Subjects			
Adults (18-64 years)	51	22	154
From 65-84 years	42	21	155
Age Continuous Units: Years			
arithmetic mean	62.4	64.5	
standard deviation	± 8.88	± 8.05	-
Sex: Female, Male Units: Participants			
Female	39	22	125
Male	54	21	184
Race (NIH/OMB) Units: Subjects			
Asian	3	4	18
Black or African American	6	7	20
White	82	30	256
Unknown or Not Reported	2	2	15
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	5	1	9
Not Hispanic or Latino	63	31	203
Unknown or Not Reported	25	11	97

End points

End points reporting groups

Reporting group title	Nivolumab
Reporting group description:	
Nivolumab monotherapy 240 mg Q2W administered until completion of 6 cycles (1 cycle=4 weeks)	
Reporting group title	Nivolumab + Dasatinib
Reporting group description:	
Nivolumab 240 mg Q2W + Dasatinib 100 mg QD, administered until completion of 6 cycles (1 cycle=4 weeks)	
Reporting group title	Nivolumab + BMS986016
Reporting group description:	
Nivolumab 240 mg Q2W + BMS986016 20 mg Q2W, administered until completion of 6 cycles (1 cycle=4 weeks)	
Reporting group title	Nivolumab + Ipilimumab
Reporting group description:	
Nivolumab 240 mg Q2W for 12 doses + Ipilimumab 1 mg/kg Q6W for 4 doses, administered until completion of 24 weeks of study	
Reporting group title	Nivolumab + BMS986205
Reporting group description:	
Nivolumab 480 mg Q4W + BMS986205 100 mg QD, administered until completion of 6 cycles (1 cycle=4 weeks	

Primary: Objective Response Rate (ORR)

End point title	Objective Response Rate (ORR)[1]
End point description:	
ORR is defined as the percentage of subjects whose confirmed best overall response (BOR) is either a complete response (CR) or partial response (PR). BOR was assessed by investigator per RECIST1.1. Results are presented by study tracks. IO YES/NO = Prior immuno-oncology therapy exposure status. PD-L1 + = PD-L1 expression levels >=1%. PD-L1 - = PD-L1 expression levels <1%. Results for treatment groups not receiving treatment during a specific study track are indicated as 99999.	
End point type	Primary
End point timeframe:	
From first dose to 2 years following last dose (up to 30 months)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: ORR is estimated and corresponding exact two-sided 95% CI is derived based Clopper and Pearson method.

End point values	Nivolumab	Nivolumab + Dasatinib	Nivolumab + BMS986016	Nivolumab + Ipilimumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	49[2]	106[3]	18[4]	93[5]
Units: Percent of Subjects				
number (confidence interval 95%)				
Track 1 = NO IO - PD-L1 +	17.5 (7.3 to 32.8)	25.0 (0.6 to 80.6)	99999 (99999 to 99999)	0 (0.0 to 70.8)
Track 2 = NO IO - PD-L1 -	0 (0.0 to 33.6)	0 (0.0 to 33.6)	0 (0.0 to 84.2)	25.0 (5.5 to 57.2)
Track 3 = YES IO	99999 (99999 to 99999)	2.4 (0.1 to 12.9)	0 (0.0 to 20.6)	5.6 (0.1 to 27.3)

Track 4 = NO IO (after enrollment stop in 1,2,3)	99999 (99999 to 99999)	1.9 (0.0 to 10.1)	99999 (99999 to 99999)	20.0 (10.8 to 32.3)
Track 5 = YES IO (after enrollment stop in 1,2,3)	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)

Notes:

[2] - Track1=40 Track2=9 Track3=0 Track4=0 Track5=0

[3] - Track1=4 Track2=8 Track3=41 Track4=53 Track5=0

[4] - Track1=0 Track2=2 Track3=16 Track4=0 Track5=0

[5] - Track1=3 Track2=12 Track3=18 Track4=60 Track5=0

End point values	Nivolumab + BMS986205			
Subject group type	Reporting group			
Number of subjects analysed	43[6]			
Units: Percent of Subjects				
number (confidence interval 95%)				
Track 1 = NO IO - PD-L1 +	9999 (9999 to 9999)			
Track 2 = NO IO - PD-L1 -	99999 (99999 to 99999)			
Track 3 = YES IO	99999 (99999 to 99999)			
Track 4 = NO IO (after enrollment stop in 1,2,3)	99999 (99999 to 99999)			
Track 5 = YES IO (after enrollment stop in 1,2,3)	2.3 (0.1 to 12.3)			

Notes:

[6] - Track1=0 Track2=0 Track3=0 Track4=0 Track5=43

Statistical analyses

No statistical analyses for this end point

Primary: Duration of Response (DOR)

End point title	Duration of Response (DOR)[7]

End point description:

DOR, computed for all treated subjects with a confirmed BOR of CR or PR, is defined as the time between the date of first response and the date of first documented disease progression (as determined by RECIST 1.1) or death due to any cause. Results are presented by study tracks. IO YES/NO = Prior immuno-oncology therapy exposure status. PD-L1 + = PD-L1 expression levels >=1%. PD-L1 - = PD-L1 expression levels <1%. Results for treatment groups not receiving treatment during a specific study track or for which a value was not calculable are indicated as 99999.

End point type	Primary

End point timeframe:

From first dose to 2 years following last dose (up to 30 months)

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: DOR is estimated using the Kaplan-Meier (KM) product limit method. Median values of DOR, along with two-sided 95% CI, is computed based on a log-log transformation method.

End point values	Nivolumab	Nivolumab + Dasatinib	Nivolumab + BMS986016	Nivolumab + Ipilimumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7[8]	3[9]	0[10]	16[11]
Units: Months				
median (confidence interval 95%)				
Track 1 =NO IO - PD-L1 +	12.81 (0.03 to 99999)	8.57 (-99999 to 99999)	(to)	99999 (99999 to 99999)
Track 2 = NO IO - PD-L1 -	99999 (99999 to 99999)	99999 (99999 to 99999)	(to)	99999 (99999 to 99999)
Track 3 = YES IO	99999 (99999 to 99999)	99999 (99999 to 99999)	(to)	99999 (99999 to 99999)
Track 4 = NO IO (after enrollment stop in 1,2,3)	99999 (99999 to 99999)	99999 (99999 to 99999)	(to)	12.65 (8.77 to 99999)
Track 5 = YES IO (after enrollment stop in 1,2,3)	99999 (99999 to 99999)	99999 (99999 to 99999)	(to)	99999 (99999 to 99999)

Notes:

[8] - Track1=7
Track2=0
Track3=0
Track4=0
Track5=0
[9] - Track1=1
Track2=0
Track3=1
Track4=1
Track5=0
[10] - Track1=0
Track2=0
Track3=0
Track4=0
Track5=0
[11] - Track1=0
Track2=3
Track3=1
Track4=12
Track5=0

End point values	Nivolumab + BMS986205			
Subject group type	Reporting group			
Number of subjects analysed	1[12]			
Units: Months				
median (confidence interval 95%)				
Track 1 =NO IO - PD-L1 +	99999 (99999 to 99999)			
Track 2 = NO IO - PD-L1 -	99999 (99999 to 99999)			
Track 3 = YES IO	99999 (99999 to 99999)			
Track 4 = NO IO (after enrollment stop in 1,2,3)	99999 (99999 to 99999)			
Track 5 = YES IO (after enrollment stop in 1,2,3)	3.75 (-99999 to 99999)			

Notes:

[12] - Track1=0
Track2=0
Track3=0
Track4=0
Track5=1

Statistical analyses

No statistical analyses for this end point

Primary: Progression Free Survival Rate (PFSR) at 24 Weeks

End point title	Progression Free Survival Rate (PFSR) at 24 Weeks[13]

End point description:

The PFSR at 24 weeks is defined as the proportion of treated subjects remaining progression free and surviving at 24 weeks since the first dosing date. Results are presented by study tracks and only for the treatment groups with a sufficient number of subjects remaining progression-free during the timeframe (n>=5). IO YES/NO = Prior immuno-oncology therapy exposure status. PD-L1 + = PD-L1 expression levels >=1%. PD-L1 - = PD-L1 expression levels <1%. Results for treatment groups not receiving treatment during a specific study track or with an insufficient number of subjects remaining progression-free are indicated as 99999.

End point type	Primary

End point timeframe:

From first dose to 24 weeks after first dose

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: PFSR at 24 weeks is derived from the Kaplan Meier estimate and corresponding CIs are derived based on Greenwood formula for variance derivation and on log-log transformation applied on the survivor function.

End point values	Nivolumab	Nivolumab + Dasatinib	Nivolumab + BMS986016	Nivolumab + Ipilimumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	49[14]	106[15]	18[16]	93[17]
Units: Proportion of Participants				
number (confidence interval 95%)				
Track 1 = NO IO - PD-L1 +	0.302 (0.164 to 0.451)	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)
Track 2 = NO IO - PD-L1 -	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)	0.455 (0.167 to 0.707)
Track 3 = YES IO	99999 (99999 to 99999)	0.191 (0.079 to 0.340)	99999 (99999 to 99999)	99999 (99999 to 99999)
Track 4 = NO IO (after enrollment stop in 1,2,3)	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)	0.391 (0.265 to 0.514)
Track 5 = YES IO (after enrollment stop in 1,2,3)	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)

Notes:

[14] - Track1=40 Track2=9 Track3=0 Track4=0 Track5=0

[15] - Track1=4 Track2=8 Track3=41 Track4=53 Track5=0

[16] - Track1=0 Track2=2 Track3=16 Track4=0 Track5=0

[17] - Track1=3 Track2=12 Track3=18 Track4=60 Track5=0

End point values	Nivolumab + BMS986205			
Subject group type	Reporting group			
Number of subjects analysed	43[18]			
Units: Proportion of Participants				
number (confidence interval 95%)				
Track 1 = NO IO - PD-L1 +	99999 (99999 to 99999)			
Track 2 = NO IO - PD-L1 -	99999 (99999 to 99999)			
Track 3 = YES IO	99999 (99999 to 99999)			
Track 4 = NO IO (after enrollment stop in 1,2,3)	99999 (99999 to 99999)			

Track 5 = YES IO (after enrollment stop in 1,2,3)	0.111 (0.036 to 0.235)			

Notes:

[18] - Track1=0 Track2=0 Track3=0 Track4=0 Track5=43

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Experiencing Adverse Events (AEs)

End point title	Percentage of Subjects Experiencing Adverse Events (AEs)

End point description:

This outcome measure describes the percentage of subjects who experienced any grade, all causality AEs during the specified time frame

End point type	Secondary

End point timeframe:

From first dose to 100 days following last dose

End point values	Nivolumab	Nivolumab + Dasatinib	Nivolumab + BMS986016	Nivolumab + Ipilimumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	49	106	18	93
Units: Percent of Subjects				
number (not applicable)	100.0	100.0	100.0	98.9

End point values	Nivolumab + BMS986205			
Subject group type	Reporting group			
Number of subjects analysed	43			
Units: Percent of Subjects				
number (not applicable)	100.0			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Experiencing Serious Adverse Events (SAEs)

End point title	Percentage of Subjects Experiencing Serious Adverse Events (SAEs)

End point description:

This outcome measure describes the percentage of subjects who experienced any grade, all causality SAEs during the specified time frame

End point type	Secondary

End point timeframe:

From first dose to 100 days following last dose

End point values	Nivolumab	Nivolumab + Dasatinib	Nivolumab + BMS986016	Nivolumab + Ipilimumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	49	106	18	93
Units: Percent of Subjects				
number (not applicable)	57.1	53.8	61.1	58.1

End point values	Nivolumab + BMS986205			
Subject group type	Reporting group			
Number of subjects analysed	43			
Units: Percent of Subjects				
number (not applicable)	60.5			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Experiencing Adverse Events (AEs) Leading to Discontinuation

End point title	Percentage of Subjects Experiencing Adverse Events (AEs) Leading to Discontinuation

End point description:

This outcome measure describes the percentage of subjects who experienced all causality AEs leading to discontinuation of study therapy during the specified time frame

End point type	Secondary

End point timeframe:

From first dose to 100 days following last dose

End point values	Nivolumab	Nivolumab + Dasatinib	Nivolumab + BMS986016	Nivolumab + Ipilimumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	49	106	18	93
Units: Percent of Subjects				
number (not applicable)	14.3	23.6	5.6	11.8

End point values	Nivolumab +			

	BMS986205			
Subject group type	Reporting group			
Number of subjects analysed	43			
Units: Percent of Subjects				
number (not applicable)	14.0			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Experiencing Death

End point title	Percentage of Subjects Experiencing Death

End point description:

This outcome measure describes the percentage of subjects who died (due to any cause) during the specified time frame

End point type	Secondary

End point timeframe:

From first dose to up to 45 months following first dose

End point values	Nivolumab	Nivolumab + Dasatinib	Nivolumab + BMS986016	Nivolumab + Ipilimumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	49	106	18	93
Units: Percent of Subjects				
number (not applicable)	57.1	55.7	66.7	46.2

End point values	Nivolumab + BMS986205			
Subject group type	Reporting group			
Number of subjects analysed	43			
Units: Percent of Subjects				
number (not applicable)	62.8			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects Experiencing Laboratory Abnormalities in Hepatic Tests

End point title	Number of Subjects Experiencing Laboratory Abnormalities in Hepatic Tests

End point description:

The following measurements will be considered laboratory abnormalities for hepatic tests: - ALT or AST > 3 x ULN, > 5 x ULN, > 10 x ULN and > 20 x ULN - Total bilirubin > 2 x ULN - Concurrent (within 1 day) ALT or AST > 3 x ULN and total bilirubin > 2 x ULN - Concurrent (within 30 days) ALT or AST > 3 x ULN and total bilirubin > 2 x ULN ALT=Alanine aminotransferase AST=Aspartate aminotransferase ULN=Upper Limit of Normal

End point type	Secondary

End point timeframe:

From first dose to 100 days following last dose

End point values	Nivolumab	Nivolumab + Dasatinib	Nivolumab + BMS986016	Nivolumab + Ipilimumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	49	106	18	93
Units: Subjects				
ALT OR AST > 3XULN	4	3	1	5
ALT OR AST > 5XULN	2	0	0	3
ALT OR AST > 10XULN	2	0	0	1
ALT OR AST > 20XULN	0	0	0	1
TOTAL BILIRUBIN > 2XULN	1	0	0	2
(1 day) ALT or AST>3x ULN and total bilir.>2x ULN	0	0	0	2
(30 day) ALT or AST>3x ULN and total bilir.>2x ULN	0	0	0	2

End point values	Nivolumab + BMS986205			
Subject group type	Reporting group			
Number of subjects analysed	43			
Units: Subjects				
ALT OR AST > 3XULN	3			
ALT OR AST > 5XULN	2			
ALT OR AST > 10XULN	2			
ALT OR AST > 20XULN	1			
TOTAL BILIRUBIN > 2XULN	3			
(1 day) ALT or AST>3x ULN and total bilir.>2x ULN	2			
(30 day) ALT or AST>3x ULN and total bilir.>2x ULN	2			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects Experiencing Laboratory Abnormalities in Thyroid Tests

End point title	Number of Subjects Experiencing Laboratory Abnormalities in

	Thyroid Tests

End point description:

The following measurements will be considered laboratory abnormalities for thyroid tests:
- TSH value > ULN and
    - With baseline TSH value ≤ ULN
    - At least one T3/T4 test value < LLN
- Low TSH < LLN and
    - With baseline TSH value ≥ LLN
    - At least one T3/T4 test value > ULN

TSH = thyroid stimulating hormone
ULN=Upper Limit of Normal
LLN=Lower Limit of Normal
T3=Triiodothyronine
T4=Thyroxin

End point type	Secondary

End point timeframe:

From first dose to 100 days following last dose

End point values	Nivolumab	Nivolumab + Dasatinib	Nivolumab + BMS986016	Nivolumab + Ipilimumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	29	76	14	75
Units: Subjects				
TSH > ULN	9	16	3	24
TSH > ULN WITH TSH <= ULN AT BASELINE	6	9	1	17
TSH > ULN AT LEAST 1 FT3/FT4 VALUE < LLN	4	3	1	8
TSH < LLN	5	3	0	20
TSH < LLN WITH TSH >= LLN AT BASELINE	5	1	0	16
TSH < LLN AT LEAST 1 FT3/FT4 VALUE > ULN	3	1	0	5

End point values	Nivolumab + BMS986205			
Subject group type	Reporting group			
Number of subjects analysed	35			
Units: Subjects				
TSH > ULN	9			
TSH > ULN WITH TSH <= ULN AT BASELINE	6			
TSH > ULN AT LEAST 1 FT3/FT4 VALUE < LLN	6			
TSH < LLN	4			
TSH < LLN WITH TSH >= LLN AT BASELINE	4			
TSH < LLN AT LEAST 1 FT3/FT4 VALUE > ULN	0			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Deaths = collected from first dose to up to 45 months following first dose
Serious adverse events and other adverse events = collected from start of treatment up to 100 days of discontinuation of dosing.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	22.1

Reporting groups

Reporting group title	Nivolumab

Reporting group description:

Nivolumab monotherapy 240 mg Q2W administered until completion of 6 cycles (1 cycle=4 weeks)

Reporting group title	Nivolumab + Dasatinib

Reporting group description:

Nivolumab 240 mg Q2W + Dasatinib 100 mg QD, administered until completion of 6 cycles (1 cycle=4 weeks)

Reporting group title	Nivolumab + BMS986016

Reporting group description:

Nivolumab 240 mg Q2W + BMS986016 20 mg Q2W, administered until completion of 6 cycles (1 cycle=4 weeks)

Reporting group title	Nivolumab + Ipilimumab

Reporting group description:

Nivolumab 240 mg Q2W for 12 doses + Ipilimumab 1 mg/kg Q6W for 4 doses, administered until completion of 24 weeks of study

Reporting group title	Nivolumab + BMS986205

Reporting group description:

Nivolumab 480 mg Q4W + BMS986205 100 mg QD, administered until completion of 6 cycles (1 cycle=4 weeks)

Serious adverse events	Nivolumab	Nivolumab + Dasatinib	Nivolumab + BMS986016
Total subjects affected by serious adverse events			
subjects affected / exposed	28 / 49 (57.14%)	57 / 106 (53.77%)	11 / 18 (61.11%)
number of deaths (all causes)	28	59	12
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cancer pain			

subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Malignant neoplasm progression			
subjects affected / exposed	12 / 49 (24.49%)	29 / 106 (27.36%)	4 / 18 (22.22%)
occurrences causally related to treatment / all	0 / 12	0 / 30	0 / 4
deaths causally related to treatment / all	0 / 11	0 / 27	0 / 4
Malignant pleural effusion			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to meninges			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasm progression			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Second primary malignancy			
subjects affected / exposed	1 / 49 (2.04%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Tumour pain			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			

subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic hypotension			
subjects affected / exposed	1 / 49 (2.04%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior vena cava syndrome			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Euthanasia			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Fatigue			
subjects affected / exposed	1 / 49 (2.04%)	2 / 106 (1.89%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	1 / 49 (2.04%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza like illness			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			

subjects affected / exposed	1 / 49 (2.04%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 49 (0.00%)	3 / 106 (2.83%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Reproductive system and breast disorders			
Scrotal oedema			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Atelectasis			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchial obstruction			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			

subjects affected / exposed	2 / 49 (4.08%)	0 / 106 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	2 / 49 (4.08%)	7 / 106 (6.60%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 8	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	0 / 49 (0.00%)	2 / 106 (1.89%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 49 (0.00%)	2 / 106 (1.89%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	1 / 49 (2.04%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung consolidation			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagobronchial fistula			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	2 / 49 (4.08%)	7 / 106 (6.60%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 2	3 / 7	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pneumonitis			

subjects affected / exposed	3 / 49 (6.12%)	6 / 106 (5.66%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	3 / 3	6 / 8	1 / 1
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Pneumothorax			
subjects affected / exposed	1 / 49 (2.04%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	4 / 49 (8.16%)	0 / 106 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	1 / 49 (2.04%)	2 / 106 (1.89%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	2 / 49 (4.08%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	1 / 49 (2.04%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			

Blood bilirubin increased			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 49 (2.04%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Human chorionic gonadotropin positive			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transaminases increased			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Ankle fracture			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	1 / 49 (2.04%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			

subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Overdose			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac tamponade			
subjects affected / exposed	1 / 49 (2.04%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocarditis			

subjects affected / exposed	1 / 49 (2.04%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	3 / 49 (6.12%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 3	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachycardia			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Brachial plexopathy			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral ischaemia			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	1 / 49 (2.04%)	1 / 106 (0.94%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 2	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial paralysis			

subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	1 / 49 (2.04%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polyneuropathy			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Neutropenia			

subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Vision blurred			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Visual impairment			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 49 (0.00%)	2 / 106 (1.89%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal obstruction			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			

subjects affected / exposed	0 / 49 (0.00%)	3 / 106 (2.83%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal food impaction			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritoneal haemorrhage			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	1 / 49 (2.04%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis			
subjects affected / exposed	2 / 49 (4.08%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Stevens-Johnson syndrome			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			

Acute kidney injury			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoparathyroidism			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypophysitis			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	2 / 49 (4.08%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	1 / 49 (2.04%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Flank pain			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			
subjects affected / exposed	1 / 49 (2.04%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Musculoskeletal chest pain			
subjects affected / exposed	1 / 49 (2.04%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteolysis			
subjects affected / exposed	1 / 49 (2.04%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sjogren's syndrome			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain abscess			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	1 / 49 (2.04%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocolitis infectious			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			

subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis streptococcal			
subjects affected / exposed	1 / 49 (2.04%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	3 / 49 (6.12%)	2 / 106 (1.89%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 3	2 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural infection			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	1 / 49 (2.04%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Septic shock			
subjects affected / exposed	0 / 49 (0.00%)	2 / 106 (1.89%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			

subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 49 (2.04%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic ketoacidosis			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	1 / 49 (2.04%)	1 / 106 (0.94%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	1 / 49 (2.04%)	2 / 106 (1.89%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			

subjects affected / exposed	0 / 49 (0.00%)	2 / 106 (1.89%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Nivolumab + Ipilimumab	Nivolumab + BMS986205	
Total subjects affected by serious adverse events			
subjects affected / exposed	54 / 93 (58.06%)	26 / 43 (60.47%)	
number of deaths (all causes)	43	27	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cancer pain			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung neoplasm malignant			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant neoplasm progression			
subjects affected / exposed	20 / 93 (21.51%)	13 / 43 (30.23%)	
occurrences causally related to treatment / all	0 / 20	0 / 15	
deaths causally related to treatment / all	0 / 20	0 / 12	
Malignant pleural effusion			
subjects affected / exposed	2 / 93 (2.15%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metastases to meninges			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Neoplasm progression			
subjects affected / exposed	0 / 93 (0.00%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Second primary malignancy			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tumour pain			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Orthostatic hypotension			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Superior vena cava syndrome			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Euthanasia			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Fatigue			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza like illness			
subjects affected / exposed	0 / 93 (0.00%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema peripheral			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	3 / 93 (3.23%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	1 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Scrotal oedema			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			

subjects affected / exposed	4 / 93 (4.30%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Atelectasis			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchial obstruction			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	5 / 93 (5.38%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	2 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoptysis			
subjects affected / exposed	2 / 93 (2.15%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxia			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Interstitial lung disease			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung consolidation			

subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagobronchial fistula			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	3 / 93 (3.23%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonitis			
subjects affected / exposed	3 / 93 (3.23%)	3 / 43 (6.98%)	
occurrences causally related to treatment / all	3 / 3	3 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax			
subjects affected / exposed	0 / 93 (0.00%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	1 / 93 (1.08%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Respiratory distress			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	1 / 93 (1.08%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Psychiatric disorders			
Confusional state			

subjects affected / exposed	0 / 93 (0.00%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delirium			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental status changes			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Blood bilirubin increased			
subjects affected / exposed	0 / 93 (0.00%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Human chorionic gonadotropin positive			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transaminases increased			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Ankle fracture			

subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infusion related reaction			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Overdose			
subjects affected / exposed	1 / 93 (1.08%)	2 / 43 (4.65%)	
occurrences causally related to treatment / all	1 / 1	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subdural haematoma			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	3 / 93 (3.23%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	1 / 7	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial flutter			

subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac tamponade			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocarditis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial effusion			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular tachycardia			
subjects affected / exposed	1 / 93 (1.08%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachycardia			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Brachial plexopathy			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral ischaemia			

subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebrovascular accident			
subjects affected / exposed	0 / 93 (0.00%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Facial paralysis			
subjects affected / exposed	0 / 93 (0.00%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage intracranial			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic stroke			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 93 (0.00%)	2 / 43 (4.65%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyneuropathy			

subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	1 / 93 (1.08%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal cord compression			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	1 / 93 (1.08%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Vision blurred			
subjects affected / exposed	0 / 93 (0.00%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Visual impairment			
subjects affected / exposed	0 / 93 (0.00%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 93 (1.08%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Constipation			
subjects affected / exposed	0 / 93 (0.00%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	2 / 93 (2.15%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestinal obstruction			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal food impaction			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritoneal haemorrhage			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis			

subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperbilirubinaemia			
subjects affected / exposed	0 / 93 (0.00%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Stevens-Johnson syndrome			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	2 / 93 (2.15%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoparathyroidism			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypophysitis			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthralgia			

subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Back pain			
subjects affected / exposed	0 / 93 (0.00%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Flank pain			
subjects affected / exposed	0 / 93 (0.00%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Muscular weakness			
subjects affected / exposed	1 / 93 (1.08%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal chest pain			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteolysis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	0 / 93 (0.00%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sjogren's syndrome			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Appendicitis			

subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain abscess			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile colitis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolitis infectious			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			
subjects affected / exposed	0 / 93 (0.00%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pharyngitis streptococcal			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	5 / 93 (5.38%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 6	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia bacterial			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural infection			

subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	2 / 93 (2.15%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	2 / 93 (2.15%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal infection			
subjects affected / exposed	0 / 93 (0.00%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ketoacidosis			

subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Failure to thrive			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hyperglycaemia			
subjects affected / exposed	0 / 93 (0.00%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	1 / 93 (1.08%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Nivolumab	Nivolumab + Dasatinib	Nivolumab + BMS986016
Total subjects affected by non-serious adverse events			
subjects affected / exposed	46 / 49 (93.88%)	98 / 106 (92.45%)	18 / 18 (100.00%)
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	2 / 49 (4.08%)	1 / 106 (0.94%)	1 / 18 (5.56%)
occurrences (all)	2	1	1
Hypertension			
subjects affected / exposed	2 / 49 (4.08%)	6 / 106 (5.66%)	0 / 18 (0.00%)
occurrences (all)	2	9	0
Hypotension			

subjects affected / exposed	3 / 49 (6.12%)	2 / 106 (1.89%)	0 / 18 (0.00%)
occurrences (all)	3	2	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	7 / 49 (14.29%)	18 / 106 (16.98%)	0 / 18 (0.00%)
occurrences (all)	9	21	0
Chest discomfort			
subjects affected / exposed	0 / 49 (0.00%)	2 / 106 (1.89%)	2 / 18 (11.11%)
occurrences (all)	0	2	2
Chest pain			
subjects affected / exposed	4 / 49 (8.16%)	7 / 106 (6.60%)	1 / 18 (5.56%)
occurrences (all)	5	7	1
Chills			
subjects affected / exposed	0 / 49 (0.00%)	11 / 106 (10.38%)	1 / 18 (5.56%)
occurrences (all)	0	15	1
Early satiety			
subjects affected / exposed	0 / 49 (0.00%)	2 / 106 (1.89%)	1 / 18 (5.56%)
occurrences (all)	0	2	1
Fatigue			
subjects affected / exposed	17 / 49 (34.69%)	51 / 106 (48.11%)	5 / 18 (27.78%)
occurrences (all)	24	53	5
Oedema			
subjects affected / exposed	0 / 49 (0.00%)	7 / 106 (6.60%)	0 / 18 (0.00%)
occurrences (all)	0	8	0
Oedema peripheral			
subjects affected / exposed	7 / 49 (14.29%)	8 / 106 (7.55%)	1 / 18 (5.56%)
occurrences (all)	9	9	1
Pyrexia			
subjects affected / exposed	4 / 49 (8.16%)	18 / 106 (16.98%)	1 / 18 (5.56%)
occurrences (all)	6	30	1
Non-Cardiac chest pain			
subjects affected / exposed	1 / 49 (2.04%)	6 / 106 (5.66%)	0 / 18 (0.00%)
occurrences (all)	1	6	0
Immune system disorders			

Hypersensitivity			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	1 / 18 (5.56%)
occurrences (all)	0	1	1
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	12 / 49 (24.49%)	21 / 106 (19.81%)	2 / 18 (11.11%)
occurrences (all)	14	24	2
Dyspnoea			
subjects affected / exposed	16 / 49 (32.65%)	34 / 106 (32.08%)	1 / 18 (5.56%)
occurrences (all)	18	40	1
Dyspnoea exertional			
subjects affected / exposed	2 / 49 (4.08%)	8 / 106 (7.55%)	2 / 18 (11.11%)
occurrences (all)	2	8	2
Haemoptysis			
subjects affected / exposed	6 / 49 (12.24%)	8 / 106 (7.55%)	0 / 18 (0.00%)
occurrences (all)	7	8	0
Hypoxia			
subjects affected / exposed	2 / 49 (4.08%)	6 / 106 (5.66%)	0 / 18 (0.00%)
occurrences (all)	2	6	0
Nasal congestion			
subjects affected / exposed	1 / 49 (2.04%)	2 / 106 (1.89%)	0 / 18 (0.00%)
occurrences (all)	1	2	0
Oropharyngeal pain			
subjects affected / exposed	2 / 49 (4.08%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	2	1	0
Pleural effusion			
subjects affected / exposed	2 / 49 (4.08%)	20 / 106 (18.87%)	1 / 18 (5.56%)
occurrences (all)	2	26	1
Pneumonia aspiration			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Pneumonitis			
subjects affected / exposed	1 / 49 (2.04%)	3 / 106 (2.83%)	1 / 18 (5.56%)
occurrences (all)	1	4	1
Productive cough			

subjects affected / exposed	7 / 49 (14.29%)	11 / 106 (10.38%)	0 / 18 (0.00%)
occurrences (all)	9	13	0
Pulmonary embolism			
subjects affected / exposed	0 / 49 (0.00%)	2 / 106 (1.89%)	1 / 18 (5.56%)
occurrences (all)	0	2	1
Wheezing			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Upper-Airway cough syndrome			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	1 / 18 (5.56%)
occurrences (all)	0	1	1
Psychiatric disorders			
Anxiety			
subjects affected / exposed	7 / 49 (14.29%)	15 / 106 (14.15%)	0 / 18 (0.00%)
occurrences (all)	7	15	0
Confusional state			
subjects affected / exposed	3 / 49 (6.12%)	5 / 106 (4.72%)	0 / 18 (0.00%)
occurrences (all)	4	5	0
Depression			
subjects affected / exposed	2 / 49 (4.08%)	5 / 106 (4.72%)	0 / 18 (0.00%)
occurrences (all)	2	5	0
Insomnia			
subjects affected / exposed	7 / 49 (14.29%)	11 / 106 (10.38%)	0 / 18 (0.00%)
occurrences (all)	8	11	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	4 / 49 (8.16%)	8 / 106 (7.55%)	0 / 18 (0.00%)
occurrences (all)	5	8	0
Amylase increased			
subjects affected / exposed	4 / 49 (8.16%)	8 / 106 (7.55%)	1 / 18 (5.56%)
occurrences (all)	7	9	1
Aspartate aminotransferase increased			
subjects affected / exposed	6 / 49 (12.24%)	7 / 106 (6.60%)	1 / 18 (5.56%)
occurrences (all)	7	7	1
Blood alkaline phosphatase increased			

subjects affected / exposed	3 / 49 (6.12%)	3 / 106 (2.83%)	0 / 18 (0.00%)
occurrences (all)	3	3	0
Blood bilirubin increased			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	2 / 49 (4.08%)	3 / 106 (2.83%)	1 / 18 (5.56%)
occurrences (all)	2	3	1
Blood thyroid stimulating hormone increased			
subjects affected / exposed	2 / 49 (4.08%)	0 / 106 (0.00%)	1 / 18 (5.56%)
occurrences (all)	2	0	1
Lipase increased			
subjects affected / exposed	2 / 49 (4.08%)	6 / 106 (5.66%)	0 / 18 (0.00%)
occurrences (all)	2	6	0
Lymphocyte count decreased			
subjects affected / exposed	2 / 49 (4.08%)	2 / 106 (1.89%)	1 / 18 (5.56%)
occurrences (all)	3	3	1
Weight decreased			
subjects affected / exposed	7 / 49 (14.29%)	18 / 106 (16.98%)	0 / 18 (0.00%)
occurrences (all)	7	19	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	1 / 49 (2.04%)	3 / 106 (2.83%)	1 / 18 (5.56%)
occurrences (all)	1	3	1
Cardiac disorders			
Tachycardia			
subjects affected / exposed	3 / 49 (6.12%)	4 / 106 (3.77%)	0 / 18 (0.00%)
occurrences (all)	4	5	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	7 / 49 (14.29%)	14 / 106 (13.21%)	1 / 18 (5.56%)
occurrences (all)	7	14	1
Dizziness postural			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Dysgeusia			

subjects affected / exposed	2 / 49 (4.08%)	10 / 106 (9.43%)	0 / 18 (0.00%)
occurrences (all)	2	11	0
Headache			
subjects affected / exposed	12 / 49 (24.49%)	16 / 106 (15.09%)	2 / 18 (11.11%)
occurrences (all)	14	18	2
Hypoaesthesia			
subjects affected / exposed	3 / 49 (6.12%)	2 / 106 (1.89%)	0 / 18 (0.00%)
occurrences (all)	3	3	0
Peripheral motor neuropathy			
subjects affected / exposed	0 / 49 (0.00%)	2 / 106 (1.89%)	1 / 18 (5.56%)
occurrences (all)	0	3	1
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 49 (0.00%)	4 / 106 (3.77%)	1 / 18 (5.56%)
occurrences (all)	0	4	1
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	8 / 49 (16.33%)	25 / 106 (23.58%)	2 / 18 (11.11%)
occurrences (all)	11	34	2
Eye disorders			
Vision blurred			
subjects affected / exposed	3 / 49 (6.12%)	3 / 106 (2.83%)	0 / 18 (0.00%)
occurrences (all)	3	4	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	1 / 49 (2.04%)	1 / 106 (0.94%)	1 / 18 (5.56%)
occurrences (all)	1	1	1
Abdominal distension			
subjects affected / exposed	1 / 49 (2.04%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	1	0
Abdominal pain			
subjects affected / exposed	5 / 49 (10.20%)	11 / 106 (10.38%)	2 / 18 (11.11%)
occurrences (all)	7	15	2
Abdominal pain upper			
subjects affected / exposed	3 / 49 (6.12%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	3	1	0
Constipation			

subjects affected / exposed	9 / 49 (18.37%)	33 / 106 (31.13%)	1 / 18 (5.56%)
occurrences (all)	11	38	1
Diarrhoea			
subjects affected / exposed	15 / 49 (30.61%)	32 / 106 (30.19%)	5 / 18 (27.78%)
occurrences (all)	25	43	5
Dry mouth			
subjects affected / exposed	1 / 49 (2.04%)	1 / 106 (0.94%)	2 / 18 (11.11%)
occurrences (all)	1	1	2
Dyspepsia			
subjects affected / exposed	3 / 49 (6.12%)	3 / 106 (2.83%)	1 / 18 (5.56%)
occurrences (all)	3	4	1
Mouth ulceration			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Nausea			
subjects affected / exposed	17 / 49 (34.69%)	45 / 106 (42.45%)	3 / 18 (16.67%)
occurrences (all)	20	60	3
Stomatitis			
subjects affected / exposed	1 / 49 (2.04%)	4 / 106 (3.77%)	2 / 18 (11.11%)
occurrences (all)	3	4	2
Tongue dysplasia			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Vomiting			
subjects affected / exposed	9 / 49 (18.37%)	26 / 106 (24.53%)	1 / 18 (5.56%)
occurrences (all)	11	30	2
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 49 (0.00%)	6 / 106 (5.66%)	1 / 18 (5.56%)
occurrences (all)	0	6	1
Dry skin			

subjects affected / exposed	4 / 49 (8.16%)	6 / 106 (5.66%)	1 / 18 (5.56%)
occurrences (all)	4	6	1
Hyperhidrosis			
subjects affected / exposed	2 / 49 (4.08%)	2 / 106 (1.89%)	0 / 18 (0.00%)
occurrences (all)	2	3	0
Night sweats			
subjects affected / exposed	0 / 49 (0.00%)	1 / 106 (0.94%)	1 / 18 (5.56%)
occurrences (all)	0	1	1
Pruritus			
subjects affected / exposed	8 / 49 (16.33%)	11 / 106 (10.38%)	1 / 18 (5.56%)
occurrences (all)	12	15	1
Rash			
subjects affected / exposed	5 / 49 (10.20%)	17 / 106 (16.04%)	3 / 18 (16.67%)
occurrences (all)	7	19	3
Rash maculo-papular			
subjects affected / exposed	2 / 49 (4.08%)	2 / 106 (1.89%)	0 / 18 (0.00%)
occurrences (all)	2	2	0
Rash pruritic			
subjects affected / exposed	1 / 49 (2.04%)	4 / 106 (3.77%)	1 / 18 (5.56%)
occurrences (all)	1	4	1
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	0 / 49 (0.00%)	2 / 106 (1.89%)	1 / 18 (5.56%)
occurrences (all)	0	2	1
Hypothyroidism			
subjects affected / exposed	4 / 49 (8.16%)	4 / 106 (3.77%)	0 / 18 (0.00%)
occurrences (all)	4	4	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	12 / 49 (24.49%)	11 / 106 (10.38%)	1 / 18 (5.56%)
occurrences (all)	14	14	1
Back pain			
subjects affected / exposed	10 / 49 (20.41%)	17 / 106 (16.04%)	1 / 18 (5.56%)
occurrences (all)	11	18	1
Flank pain			

subjects affected / exposed	0 / 49 (0.00%)	5 / 106 (4.72%)	1 / 18 (5.56%)
occurrences (all)	0	5	1
Musculoskeletal chest pain			
subjects affected / exposed	3 / 49 (6.12%)	7 / 106 (6.60%)	1 / 18 (5.56%)
occurrences (all)	3	7	1
Musculoskeletal pain			
subjects affected / exposed	8 / 49 (16.33%)	10 / 106 (9.43%)	1 / 18 (5.56%)
occurrences (all)	8	11	1
Musculoskeletal stiffness			
subjects affected / exposed	3 / 49 (6.12%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	3	0	0
Myalgia			
subjects affected / exposed	4 / 49 (8.16%)	6 / 106 (5.66%)	1 / 18 (5.56%)
occurrences (all)	5	6	1
Neck pain			
subjects affected / exposed	1 / 49 (2.04%)	6 / 106 (5.66%)	1 / 18 (5.56%)
occurrences (all)	1	6	1
Pain in extremity			
subjects affected / exposed	7 / 49 (14.29%)	11 / 106 (10.38%)	0 / 18 (0.00%)
occurrences (all)	8	13	0
Spinal pain			
subjects affected / exposed	3 / 49 (6.12%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	3	0	0
Infections and infestations			
Bronchitis			
subjects affected / exposed	1 / 49 (2.04%)	1 / 106 (0.94%)	1 / 18 (5.56%)
occurrences (all)	2	2	1
Influenza			
subjects affected / exposed	2 / 49 (4.08%)	0 / 106 (0.00%)	0 / 18 (0.00%)
occurrences (all)	3	0	0
Laryngitis			
subjects affected / exposed	0 / 49 (0.00%)	0 / 106 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Nasopharyngitis			
subjects affected / exposed	2 / 49 (4.08%)	6 / 106 (5.66%)	0 / 18 (0.00%)
occurrences (all)	2	7	0

Pneumonia			
subjects affected / exposed	3 / 49 (6.12%)	6 / 106 (5.66%)	0 / 18 (0.00%)
occurrences (all)	4	6	0
Upper respiratory tract infection			
subjects affected / exposed	3 / 49 (6.12%)	4 / 106 (3.77%)	1 / 18 (5.56%)
occurrences (all)	4	5	1
Urinary tract infection			
subjects affected / exposed	7 / 49 (14.29%)	2 / 106 (1.89%)	0 / 18 (0.00%)
occurrences (all)	8	2	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	18 / 49 (36.73%)	39 / 106 (36.79%)	5 / 18 (27.78%)
occurrences (all)	22	44	5
Dehydration			
subjects affected / exposed	1 / 49 (2.04%)	6 / 106 (5.66%)	0 / 18 (0.00%)
occurrences (all)	1	6	0
Hyperglycaemia			
subjects affected / exposed	1 / 49 (2.04%)	3 / 106 (2.83%)	1 / 18 (5.56%)
occurrences (all)	4	3	1
Hyperkalaemia			
subjects affected / exposed	1 / 49 (2.04%)	1 / 106 (0.94%)	0 / 18 (0.00%)
occurrences (all)	1	1	0
Hypocalcaemia			
subjects affected / exposed	3 / 49 (6.12%)	2 / 106 (1.89%)	0 / 18 (0.00%)
occurrences (all)	5	2	0
Hypokalaemia			
subjects affected / exposed	4 / 49 (8.16%)	6 / 106 (5.66%)	1 / 18 (5.56%)
occurrences (all)	5	8	1
Hypomagnesaemia			
subjects affected / exposed	5 / 49 (10.20%)	8 / 106 (7.55%)	0 / 18 (0.00%)
occurrences (all)	5	9	0
Hyponatraemia			
subjects affected / exposed	6 / 49 (12.24%)	10 / 106 (9.43%)	1 / 18 (5.56%)
occurrences (all)	6	13	1
Hypophosphataemia			

subjects affected / exposed	3 / 49 (6.12%)	9 / 106 (8.49%)	0 / 18 (0.00%)
occurrences (all)	3	14	0

Non-serious adverse events	Nivolumab + Ipilimumab	Nivolumab + BMS986205	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	91 / 93 (97.85%)	41 / 43 (95.35%)	
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences (all)	0	0	
Hypertension			
subjects affected / exposed	5 / 93 (5.38%)	6 / 43 (13.95%)	
occurrences (all)	7	7	
Hypotension			
subjects affected / exposed	6 / 93 (6.45%)	2 / 43 (4.65%)	
occurrences (all)	8	2	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	11 / 93 (11.83%)	1 / 43 (2.33%)	
occurrences (all)	16	1	
Chest discomfort			
subjects affected / exposed	3 / 93 (3.23%)	1 / 43 (2.33%)	
occurrences (all)	3	1	
Chest pain			
subjects affected / exposed	5 / 93 (5.38%)	2 / 43 (4.65%)	
occurrences (all)	6	3	
Chills			
subjects affected / exposed	5 / 93 (5.38%)	1 / 43 (2.33%)	
occurrences (all)	5	3	
Early satiety			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences (all)	1	0	
Fatigue			
subjects affected / exposed	44 / 93 (47.31%)	20 / 43 (46.51%)	
occurrences (all)	52	25	
Oedema			

subjects affected / exposed	1 / 93 (1.08%)	2 / 43 (4.65%)	
occurrences (all)	1	2	
Oedema peripheral			
subjects affected / exposed	8 / 93 (8.60%)	7 / 43 (16.28%)	
occurrences (all)	10	9	
Pyrexia			
subjects affected / exposed	15 / 93 (16.13%)	5 / 43 (11.63%)	
occurrences (all)	23	7	
Non-Cardiac chest pain			
subjects affected / exposed	5 / 93 (5.38%)	0 / 43 (0.00%)	
occurrences (all)	6	0	
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences (all)	0	0	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	25 / 93 (26.88%)	11 / 43 (25.58%)	
occurrences (all)	28	11	
Dyspnoea			
subjects affected / exposed	27 / 93 (29.03%)	6 / 43 (13.95%)	
occurrences (all)	32	9	
Dyspnoea exertional			
subjects affected / exposed	4 / 93 (4.30%)	1 / 43 (2.33%)	
occurrences (all)	4	1	
Haemoptysis			
subjects affected / exposed	4 / 93 (4.30%)	2 / 43 (4.65%)	
occurrences (all)	6	2	
Hypoxia			
subjects affected / exposed	6 / 93 (6.45%)	1 / 43 (2.33%)	
occurrences (all)	6	2	
Nasal congestion			
subjects affected / exposed	5 / 93 (5.38%)	1 / 43 (2.33%)	
occurrences (all)	5	1	
Oropharyngeal pain			

subjects affected / exposed	5 / 93 (5.38%)	0 / 43 (0.00%)	
occurrences (all)	6	0	
Pleural effusion			
subjects affected / exposed	4 / 93 (4.30%)	3 / 43 (6.98%)	
occurrences (all)	4	3	
Pneumonia aspiration			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences (all)	0	0	
Pneumonitis			
subjects affected / exposed	4 / 93 (4.30%)	2 / 43 (4.65%)	
occurrences (all)	4	3	
Productive cough			
subjects affected / exposed	7 / 93 (7.53%)	2 / 43 (4.65%)	
occurrences (all)	8	2	
Pulmonary embolism			
subjects affected / exposed	3 / 93 (3.23%)	0 / 43 (0.00%)	
occurrences (all)	3	0	
Wheezing			
subjects affected / exposed	6 / 93 (6.45%)	2 / 43 (4.65%)	
occurrences (all)	6	2	
Upper-Airway cough syndrome			
subjects affected / exposed	3 / 93 (3.23%)	1 / 43 (2.33%)	
occurrences (all)	3	1	
Psychiatric disorders			
Anxiety			
subjects affected / exposed	8 / 93 (8.60%)	2 / 43 (4.65%)	
occurrences (all)	9	2	
Confusional state			
subjects affected / exposed	3 / 93 (3.23%)	2 / 43 (4.65%)	
occurrences (all)	3	2	
Depression			
subjects affected / exposed	5 / 93 (5.38%)	0 / 43 (0.00%)	
occurrences (all)	5	0	
Insomnia			
subjects affected / exposed	12 / 93 (12.90%)	5 / 43 (11.63%)	
occurrences (all)	12	6	

Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	5 / 93 (5.38%)	5 / 43 (11.63%)	
occurrences (all)	5	6	
Amylase increased			
subjects affected / exposed	8 / 93 (8.60%)	0 / 43 (0.00%)	
occurrences (all)	9	0	
Aspartate aminotransferase increased			
subjects affected / exposed	6 / 93 (6.45%)	4 / 43 (9.30%)	
occurrences (all)	6	4	
Blood alkaline phosphatase increased			
subjects affected / exposed	4 / 93 (4.30%)	1 / 43 (2.33%)	
occurrences (all)	6	1	
Blood bilirubin increased			
subjects affected / exposed	1 / 93 (1.08%)	4 / 43 (9.30%)	
occurrences (all)	1	4	
Blood creatinine increased			
subjects affected / exposed	5 / 93 (5.38%)	2 / 43 (4.65%)	
occurrences (all)	6	3	
Blood thyroid stimulating hormone increased			
subjects affected / exposed	2 / 93 (2.15%)	0 / 43 (0.00%)	
occurrences (all)	2	0	
Lipase increased			
subjects affected / exposed	8 / 93 (8.60%)	2 / 43 (4.65%)	
occurrences (all)	9	2	
Lymphocyte count decreased			
subjects affected / exposed	3 / 93 (3.23%)	3 / 43 (6.98%)	
occurrences (all)	5	3	
Weight decreased			
subjects affected / exposed	15 / 93 (16.13%)	13 / 43 (30.23%)	
occurrences (all)	17	14	
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 93 (0.00%)	2 / 43 (4.65%)	
occurrences (all)	0	2	

Cardiac disorders			
Tachycardia			
subjects affected / exposed	5 / 93 (5.38%)	1 / 43 (2.33%)	
occurrences (all)	6	1	
Nervous system disorders			
Dizziness			
subjects affected / exposed	15 / 93 (16.13%)	3 / 43 (6.98%)	
occurrences (all)	18	3	
Dizziness postural			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences (all)	0	0	
Dysgeusia			
subjects affected / exposed	2 / 93 (2.15%)	2 / 43 (4.65%)	
occurrences (all)	2	2	
Headache			
subjects affected / exposed	14 / 93 (15.05%)	8 / 43 (18.60%)	
occurrences (all)	21	10	
Hypoaesthesia			
subjects affected / exposed	1 / 93 (1.08%)	1 / 43 (2.33%)	
occurrences (all)	1	1	
Peripheral motor neuropathy			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences (all)	0	0	
Peripheral sensory neuropathy			
subjects affected / exposed	4 / 93 (4.30%)	2 / 43 (4.65%)	
occurrences (all)	4	2	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	14 / 93 (15.05%)	6 / 43 (13.95%)	
occurrences (all)	16	7	
Eye disorders			
Vision blurred			
subjects affected / exposed	5 / 93 (5.38%)	1 / 43 (2.33%)	
occurrences (all)	5	1	
Gastrointestinal disorders			
Abdominal discomfort			

subjects affected / exposed	0 / 93 (0.00%)	2 / 43 (4.65%)	
occurrences (all)	0	2	
Abdominal distension			
subjects affected / exposed	5 / 93 (5.38%)	2 / 43 (4.65%)	
occurrences (all)	5	2	
Abdominal pain			
subjects affected / exposed	12 / 93 (12.90%)	6 / 43 (13.95%)	
occurrences (all)	14	6	
Abdominal pain upper			
subjects affected / exposed	4 / 93 (4.30%)	2 / 43 (4.65%)	
occurrences (all)	4	2	
Constipation			
subjects affected / exposed	26 / 93 (27.96%)	13 / 43 (30.23%)	
occurrences (all)	29	14	
Diarrhoea			
subjects affected / exposed	24 / 93 (25.81%)	11 / 43 (25.58%)	
occurrences (all)	36	13	
Dry mouth			
subjects affected / exposed	5 / 93 (5.38%)	0 / 43 (0.00%)	
occurrences (all)	6	0	
Dyspepsia			
subjects affected / exposed	4 / 93 (4.30%)	1 / 43 (2.33%)	
occurrences (all)	4	1	
Mouth ulceration			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences (all)	0	0	
Nausea			
subjects affected / exposed	27 / 93 (29.03%)	16 / 43 (37.21%)	
occurrences (all)	33	18	
Stomatitis			
subjects affected / exposed	0 / 93 (0.00%)	3 / 43 (6.98%)	
occurrences (all)	0	3	
Tongue dysplasia			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences (all)	0	0	
Vomiting			

subjects affected / exposed	20 / 93 (21.51%)	5 / 43 (11.63%)	
occurrences (all)	30	6	
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences (all)	0	0	
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	3 / 93 (3.23%)	3 / 43 (6.98%)	
occurrences (all)	3	3	
Dry skin			
subjects affected / exposed	8 / 93 (8.60%)	3 / 43 (6.98%)	
occurrences (all)	11	3	
Hyperhidrosis			
subjects affected / exposed	1 / 93 (1.08%)	3 / 43 (6.98%)	
occurrences (all)	1	4	
Night sweats			
subjects affected / exposed	3 / 93 (3.23%)	0 / 43 (0.00%)	
occurrences (all)	3	0	
Pruritus			
subjects affected / exposed	22 / 93 (23.66%)	3 / 43 (6.98%)	
occurrences (all)	28	3	
Rash			
subjects affected / exposed	15 / 93 (16.13%)	3 / 43 (6.98%)	
occurrences (all)	19	3	
Rash maculo-papular			
subjects affected / exposed	9 / 93 (9.68%)	2 / 43 (4.65%)	
occurrences (all)	11	2	
Rash pruritic			
subjects affected / exposed	2 / 93 (2.15%)	0 / 43 (0.00%)	
occurrences (all)	3	0	
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	3 / 93 (3.23%)	0 / 43 (0.00%)	
occurrences (all)	4	0	
Hypothyroidism			

subjects affected / exposed	9 / 93 (9.68%)	1 / 43 (2.33%)	
occurrences (all)	9	1	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	15 / 93 (16.13%)	6 / 43 (13.95%)	
occurrences (all)	15	7	
Back pain			
subjects affected / exposed	19 / 93 (20.43%)	8 / 43 (18.60%)	
occurrences (all)	20	8	
Flank pain			
subjects affected / exposed	3 / 93 (3.23%)	2 / 43 (4.65%)	
occurrences (all)	3	2	
Musculoskeletal chest pain			
subjects affected / exposed	4 / 93 (4.30%)	1 / 43 (2.33%)	
occurrences (all)	4	1	
Musculoskeletal pain			
subjects affected / exposed	8 / 93 (8.60%)	5 / 43 (11.63%)	
occurrences (all)	8	5	
Musculoskeletal stiffness			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences (all)	0	0	
Myalgia			
subjects affected / exposed	5 / 93 (5.38%)	5 / 43 (11.63%)	
occurrences (all)	5	5	
Neck pain			
subjects affected / exposed	1 / 93 (1.08%)	0 / 43 (0.00%)	
occurrences (all)	1	0	
Pain in extremity			
subjects affected / exposed	4 / 93 (4.30%)	3 / 43 (6.98%)	
occurrences (all)	5	3	
Spinal pain			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences (all)	0	0	
Infections and infestations			

Bronchitis			
subjects affected / exposed	3 / 93 (3.23%)	0 / 43 (0.00%)	
occurrences (all)	4	0	
Influenza			
subjects affected / exposed	1 / 93 (1.08%)	3 / 43 (6.98%)	
occurrences (all)	2	3	
Laryngitis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 43 (0.00%)	
occurrences (all)	0	0	
Nasopharyngitis			
subjects affected / exposed	2 / 93 (2.15%)	1 / 43 (2.33%)	
occurrences (all)	2	1	
Pneumonia			
subjects affected / exposed	3 / 93 (3.23%)	2 / 43 (4.65%)	
occurrences (all)	3	3	
Upper respiratory tract infection			
subjects affected / exposed	1 / 93 (1.08%)	4 / 43 (9.30%)	
occurrences (all)	2	4	
Urinary tract infection			
subjects affected / exposed	3 / 93 (3.23%)	1 / 43 (2.33%)	
occurrences (all)	6	1	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	24 / 93 (25.81%)	15 / 43 (34.88%)	
occurrences (all)	30	17	
Dehydration			
subjects affected / exposed	5 / 93 (5.38%)	4 / 43 (9.30%)	
occurrences (all)	5	4	
Hyperglycaemia			
subjects affected / exposed	4 / 93 (4.30%)	3 / 43 (6.98%)	
occurrences (all)	5	3	
Hyperkalaemia			
subjects affected / exposed	6 / 93 (6.45%)	0 / 43 (0.00%)	
occurrences (all)	7	0	
Hypocalcaemia			

subjects affected / exposed	2 / 93 (2.15%)	0 / 43 (0.00%)	
occurrences (all)	3	0	
Hypokalaemia			
subjects affected / exposed	7 / 93 (7.53%)	2 / 43 (4.65%)	
occurrences (all)	8	2	
Hypomagnesaemia			
subjects affected / exposed	11 / 93 (11.83%)	1 / 43 (2.33%)	
occurrences (all)	12	1	
Hyponatraemia			
subjects affected / exposed	13 / 93 (13.98%)	2 / 43 (4.65%)	
occurrences (all)	18	2	
Hypophosphataemia			
subjects affected / exposed	4 / 93 (4.30%)	1 / 43 (2.33%)	
occurrences (all)	6	1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
08 April 2016	Statistical study design update
27 July 2016	Inclusion/exclusion criteria update
21 September 2016	Management Algorithms for Immuno-Oncology Agents update
13 October 2016	Inclusion/exclusion criteria update
16 February 2017	Study design simplification and study tracks re-arrangement
12 April 2018	Study design changes
22 April 2019	Adjustment of Follow-up period timelines

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

This study was terminated early by sponsor for reasons unrelated to safety..
14 of the 295 participants initially received a treatment and then were re-randomized to a different, non-concomitant second treatment

Notes: